BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Telisotuzumab Adizutecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Telisotuzumab Adizutecan\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06107413-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT06107413)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  Study to Assess Adverse Events and Change in Disease Activity in Previous
 ly Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unr
 esectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil
 \, Folinic Acid\, and Bevacizumab\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-a
 dizutecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06107413
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05005403-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Telisotuzumab Adizutecan: Phase 1 readout est. (NCT05005403)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 1\, Non-Small Cell Lung Cancer
 .\nStudy: Study to Assess Adverse Events and Pharmacokinetics in Adult Par
 ticipants With Non-Small Cell Lung Cancer\, Head and Neck Squamous Cell Ca
 rcinoma and Other Solid Tumors\, Receiving Intravenous Infusion of Azirkit
 ug Alone or in Combination(s) With Budigalimab\, Bevacizumab\, or Telisotu
 zumab Adizutecan\nEstimated primary completion: July 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05005403
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614192-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT06614192)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  A Study Assessing Adverse Events and Disease Activity of Intravenously (I
 V) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Prote
 in Above Cutoff Level Above Refractory Metastatic Colorectal Cancer\nEstim
 ated primary completion: August 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06614192
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084481-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Telisotuzumab Adizutecan: Phase 1 readout est. (NCT06084481)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 1.\nStudy: Study to Assess Adv
 erse Events and Change in Disease Activity in Adult Participants With Sele
 ct Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400\nE
 stimated primary completion: September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06084481
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05029882-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Telisotuzumab Adizutecan: Phase 1 readout est. (NCT05029882)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 1\, Non-Small Cell Lung Cancer
 .\nStudy: Study to Assess Adverse Events and Change in Disease Activity in
  Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) 
 ABBV-400 as Monotherapy and in Combination With IV Bevacizumab\nEstimated 
 primary completion: November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05029882
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772623-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Telisotuzumab Adizutecan: Phase 1/2 readout est. (NCT06772623)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Study to Evaluate Adverse Events and Efficacy of Intravenous (
 IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint 
 Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous N
 SCLC With No Prior Treatment for Advanced Disease\, and No Actionable Geno
 mic Alterations\nEstimated primary completion: November 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06772623
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06464692-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Telisotuzumab Adizutecan: Phase 1 readout est. (NCT06464692)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 1\, Colorectal Cancer.\nStudy:
  Study to Assess Adverse Events and How Intravenously (IV) Infused Telisot
 uzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants 
 With Unresectable Locally Advanced/Metastatic Colorectal Cancer\nEstimated
  primary completion: December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06464692
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874282-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07874282)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: Phase II Study to Evaluate Telisotuzumab Adizutecan in Combinati
 on With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squ
 amous Non-Small-Cell Lung Cancer\nEstimated primary completion: December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-ad
 izutecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07874282
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820463-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT06820463)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  A Study to Evaluate the Adverse Events\, and Efficacy of Intravenous (IV)
  of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin\, Fluorour
 acil\, Folinic Acid/Leucovorin\, Bevacizumab\, Panitumumab in Adult Partic
 ipants With Metastatic Colorectal Cancer\nEstimated primary completion: Ma
 rch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telisotuzum
 ab-adizutecan#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06820463
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895355-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07895355)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotu
 zumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorecta
 l Cancer\nEstimated primary completion: July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07895355
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07769502-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07769502)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2.\nStudy: A Study to Assess A
 dverse Events and Change in Disease Activity With Treatment Combinations W
 ith Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary 
 Cancers\nEstimated primary completion: September 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07769502
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07525206-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Telisotuzumab Adizutecan: Phase 3 readout est. (NCT07525206)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 3\, Colorectal Cancer.\nStudy:
  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combinatio
 n With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combin
 ation With Oral Trifluridine and Tipiracil in Adult Participants With Refr
 actory Metastatic Colorectal Cancer\nEstimated primary completion: May 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-adiz
 utecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07525206
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744126-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07744126)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2.\nStudy: A Study to Assess A
 dverse Events\, Change in Disease Activity and Optimal Dose of Intravenous
  (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatm
 ent of Adult Participants With Recurrent or Metastatic Head and Neck Squam
 ous Cell Carcinoma\nEstimated primary completion: October 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07744126
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023289-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07023289)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  A Study to Assess Adverse Events and Change in Disease Activity in Adult 
 Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alon
 e or With Standard of Care in Participants With Post Adjuvant Circulating 
 Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disea
 se\nEstimated primary completion: November 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07023289
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07821684-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Telisotuzumab Adizutecan: Phase 3 readout est. (NCT07821684)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 3\, Non-Small Cell Lung Cancer
 .\nStudy: A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Comp
 ared to Standard of Care in Adult Participants Previously Treated\, EGFR W
 ildtype\, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Can
 cer\nEstimated primary completion: March 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07821684
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155187-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Telisotuzumab Adizutecan: Phase 2/3 readout est. (NCT07155187)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2/3\, Non-Small Cell Lung Canc
 er.\nStudy: A Study to Assess Adverse Events and Change in Disease Activit
 y of Intravenous (IV) Telisotuzumab Adizutecan\, Monotherapy or in Combina
 tion With Osimertinib\, Compared to Standard of Care in Adult Participants
  With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small C
 ell Lung Cancer\nEstimated primary completion: September 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07155187
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06628310-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT06628310)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2.\nStudy: A Study to Evaluate
  the Adverse Events\, Efficacy\, and Optimal Dose of Intravenous (IV) ABBV
 -400 in Combination With IV Fluorouracil\, Leucovorin\, and Budigalimab in
  Adult Participants With Locally Advanced Unresectable or Metastatic Gastr
 ic\, Gastroesophageal Junction\, or Esophageal Adenocarcinoma\nEstimated p
 rimary completion: October 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06628310
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196644-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07196644)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2.\nStudy: A Study to Assess A
 dverse Events and Change in Disease Activity in Participants 12 Years of A
 ge or Older With Locally Advanced or Metastatic Solid Tumors That Harbor M
 ET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan\
 nEstimated primary completion: December 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07196644
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490301-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Telisotuzumab Adizutecan: Phase 2/3 readout est. (NCT07490301)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2/3.\nStudy: A Study to Assess
  Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouraci
 l\, Folinic Acid\, and Oxaliplatin (FOLFOX) Compared to Standard of Care i
 n Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocar
 cinoma\nEstimated primary completion: June 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07490301
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005102-2270@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20361130
DTEND;VALUE=DATE:20361201
SUMMARY:Telisotuzumab Adizutecan: Phase 2/3 readout est. (NCT07005102)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2/3\, Non-Small Cell Lung Canc
 er.\nStudy: A Study to Assess Adverse Events\, Change in Disease Activity 
 of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as
  First-Line Treatment in Adult Participants With Locally Advanced Unresect
 able or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer\nE
 stimated primary completion: November 2036. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07005102
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
